Pub Date : 2024-04-15DOI: 10.1124/pharmrev.123.001084
Zhiwen Huang, Z. Braunstein, Jun Chen, Yingying Wei, Xiaoquan Rao, Lingli Dong, Jixin Zhong
In the era of precision medicine, Antibody-Drug Conjugates (ADCs) have emerged as a cutting-edge therapeutic strategy. These innovative compounds combine the precision of monoclonal antibodies with the potent cell-killing or immune-modulating abilities of attached drug payloads. This unique strategy not only reduces off-target toxicity but also enhances the therapeutic effectiveness of drugs. Beyond their well-established role in oncology, ADCs are now showing promising potential in addressing the unmet needs in the therapeutics of rheumatic diseases. Rheumatic diseases, a diverse group of chronic autoimmune diseases with varying etiologies, clinical presentations, and prognoses, often demand prolonged pharmacological interventions, creating a pressing need for novel, efficient and low-risk treatment options. ADCs, with their ability to precisely target the immune components, have emerged as a novel therapeutic strategy in this context. This review will provide an overview of the core components and mechanisms behind ADCs, a summary of the latest clinical trials of ADCs for the treatment if rheumatic diseases, as well as a discussion on the challenges and future prospects faced by the development of next-generation ADCs. Significance Statement There is a lack of efficient and low-risk targeted therapeutics for rheumatic diseases. Antibody-drug conjugates, a class of cutting-edge therapeutic drugs, have emerged as a promising targeted therapeutic strategy for rheumatic disease. While there is limited literature summarizing the progress of antibody-drug conjugates in the field of rheumatic disease, updating the advancements in this area provides novel insights into the development of novel anti-rheumatic drugs.
{"title":"Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates.","authors":"Zhiwen Huang, Z. Braunstein, Jun Chen, Yingying Wei, Xiaoquan Rao, Lingli Dong, Jixin Zhong","doi":"10.1124/pharmrev.123.001084","DOIUrl":"https://doi.org/10.1124/pharmrev.123.001084","url":null,"abstract":"In the era of precision medicine, Antibody-Drug Conjugates (ADCs) have emerged as a cutting-edge therapeutic strategy. These innovative compounds combine the precision of monoclonal antibodies with the potent cell-killing or immune-modulating abilities of attached drug payloads. This unique strategy not only reduces off-target toxicity but also enhances the therapeutic effectiveness of drugs. Beyond their well-established role in oncology, ADCs are now showing promising potential in addressing the unmet needs in the therapeutics of rheumatic diseases. Rheumatic diseases, a diverse group of chronic autoimmune diseases with varying etiologies, clinical presentations, and prognoses, often demand prolonged pharmacological interventions, creating a pressing need for novel, efficient and low-risk treatment options. ADCs, with their ability to precisely target the immune components, have emerged as a novel therapeutic strategy in this context. This review will provide an overview of the core components and mechanisms behind ADCs, a summary of the latest clinical trials of ADCs for the treatment if rheumatic diseases, as well as a discussion on the challenges and future prospects faced by the development of next-generation ADCs. Significance Statement There is a lack of efficient and low-risk targeted therapeutics for rheumatic diseases. Antibody-drug conjugates, a class of cutting-edge therapeutic drugs, have emerged as a promising targeted therapeutic strategy for rheumatic disease. While there is limited literature summarizing the progress of antibody-drug conjugates in the field of rheumatic disease, updating the advancements in this area provides novel insights into the development of novel anti-rheumatic drugs.","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"281 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140704095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.1124/pharmrev.123.000955
Lianne R. de Haan, Rowan F. van Golen, Michal Heger
{"title":"Molecular pathways governing the termination of liver regeneration","authors":"Lianne R. de Haan, Rowan F. van Golen, Michal Heger","doi":"10.1124/pharmrev.123.000955","DOIUrl":"https://doi.org/10.1124/pharmrev.123.000955","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"73 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.1124/pharmrev.123.000901
A. Santiso, A. Heinemann, J. Kargl
{"title":"Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4","authors":"A. Santiso, A. Heinemann, J. Kargl","doi":"10.1124/pharmrev.123.000901","DOIUrl":"https://doi.org/10.1124/pharmrev.123.000901","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"100 25","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140079729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-08DOI: 10.1124/pharmrev.120.000007
Analia Bortolozzi, G. Fico, Michael Berk, Marco Solmi, M. Fornaro, Joao Quevedo, Carlos A. Zarate, Lars V. Kessing, Eduard Vieta, André F. Carvalho
{"title":"New advances in the pharmacology and toxicology of lithium: a neurobiologically-oriented overview.","authors":"Analia Bortolozzi, G. Fico, Michael Berk, Marco Solmi, M. Fornaro, Joao Quevedo, Carlos A. Zarate, Lars V. Kessing, Eduard Vieta, André F. Carvalho","doi":"10.1124/pharmrev.120.000007","DOIUrl":"https://doi.org/10.1124/pharmrev.120.000007","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139854377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-08DOI: 10.1124/pharmrev.120.000007
Analia Bortolozzi, G. Fico, Michael Berk, Marco Solmi, M. Fornaro, Joao Quevedo, Carlos A. Zarate, Lars V. Kessing, Eduard Vieta, André F. Carvalho
{"title":"New advances in the pharmacology and toxicology of lithium: a neurobiologically-oriented overview.","authors":"Analia Bortolozzi, G. Fico, Michael Berk, Marco Solmi, M. Fornaro, Joao Quevedo, Carlos A. Zarate, Lars V. Kessing, Eduard Vieta, André F. Carvalho","doi":"10.1124/pharmrev.120.000007","DOIUrl":"https://doi.org/10.1124/pharmrev.120.000007","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"63 S291","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139794512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-30DOI: 10.1124/pharmrev.123.000831
D. Maaliki, Aneese A. Jaffa, Suzanne Nasser, Amirhossein Sahbekar, Ali H. Eid
{"title":"Adrenoceptor Desensitization: Current understanding of mechanisms","authors":"D. Maaliki, Aneese A. Jaffa, Suzanne Nasser, Amirhossein Sahbekar, Ali H. Eid","doi":"10.1124/pharmrev.123.000831","DOIUrl":"https://doi.org/10.1124/pharmrev.123.000831","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"126 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140483608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-30DOI: 10.1124/pharmrev.123.001087
Michail Kokkorakis, Emir M. Muzurović, Š. Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros
{"title":"Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies","authors":"Michail Kokkorakis, Emir M. Muzurović, Š. Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros","doi":"10.1124/pharmrev.123.001087","DOIUrl":"https://doi.org/10.1124/pharmrev.123.001087","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"106 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140484691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-05DOI: 10.1124/pharmrev.123.000967
Barbara L.F. Kaplan, A. Hoberman, William Slikker, Mary Alice Smith, Emanuela Corsini, Thomas B Knudsen, M. S. Marty, Sonya K Sobrian, Suzanne C Fitzpatrick, Marcia H Ratner, Donna L Mendrick
{"title":"Protecting Human and Animal Health: The Road From Animal Models to New Approach Methods","authors":"Barbara L.F. Kaplan, A. Hoberman, William Slikker, Mary Alice Smith, Emanuela Corsini, Thomas B Knudsen, M. S. Marty, Sonya K Sobrian, Suzanne C Fitzpatrick, Marcia H Ratner, Donna L Mendrick","doi":"10.1124/pharmrev.123.000967","DOIUrl":"https://doi.org/10.1124/pharmrev.123.000967","url":null,"abstract":"","PeriodicalId":508322,"journal":{"name":"Pharmacological Reviews","volume":"62 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139449769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：